Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira)
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Insulin degludec/liraglutide (IDegLira) is a novel combination of insulin degludec (IDeg) and liraglutide. This trial investigated the contribution of the liraglutide component of IDegLira versus IDeg alone on efficacy and safety in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: In a 26-week, double-blind trial, patients with type 2 diabetes (A1C 7.5–10.0% [58–86 mmol/mol]) on basal insulin (20–40 units) and metformin with or without sulfonylurea/glinides were randomized (1:1) to once-daily IDegLira + metformin or IDeg + metformin with titration aiming for fasting plasma glucose between 4 and 5 mmol/L. Maximum allowed doses were 50 dose steps (equal to 50 units IDeg plus 1.8 mg liraglutide) and 50 units for IDeg. The primary end point was change in A1C from baseline. RESULTS: A total of 413 patients were randomized (mean A1C 8.8% [73 mmol/mol]; BMI 33.7 kg/m2). IDeg dose, alone or as part of IDegLira, was equivalent (45 units). A1C decreased by 1.9% (21 mmol/mol) with IDegLira and by 0.9% (10 mmol/mol) with IDeg (estimated treatment difference −1.1% [95% CI −1.3, −0.8], −12 mmol/mol [95% CI −14, −9; P < 0.0001). Mean weight reduction with IDegLira was 2.7 kg vs. no weight change with IDeg, P < 0.0001. Hypoglycemia incidence was comparable (24% for IDegLira vs. 25% for IDeg). Overall adverse events were similar, and incidence of nausea was low in both groups (IDegLira 6.5% vs. IDeg 3.5%). CONCLUSIONS: IDegLira achieved glycemic control superior to that of IDeg at equivalent insulin doses without higher risk of hypoglycemia and with the benefit of weight loss. These findings establish the efficacy and safety of IDegLira and the distinct contribution of the liraglutide component.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In studies of people with type 2 diabetes inadequately controlled on basal insulin or GLP-1 RA, switching to a fi xedratio combination of basal insulin and GLP-1 RA demonstrated signi fi cant improvements in blood glucose levels and achievement of glycemic goals with fewer hypoglycemic events than with basal insulin alone (216 -220).”
Citations
Cites
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Self-citationManagement of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
Self-citationBuse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Self-citationWorld Medical Association Declaration of Helsinki
(2003) · Psychopharmacology · doi:10.1002/047086947x.oth1 · Cited by 1,332
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Inzucchi, S., Bergenstal, R., Buse, J., Diamant, M., Ferrannini, E., Nauck, M., Peters, A., Tsapas, A., Wender, R., & Matthews, D. (2013) · Diabetes Care · doi:10.2337/dc13-er02 · Cited by 805
Self-citationPeyrot, M., Barnett, A. H., Meneghini, L. F., & Schumm‐Draeger, P. ‐. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03605.x · Cited by 655
Buse, J. B., Nauck, M., Forst, T., Sheu, W. H.-H., Shenouda, S. K., Heilmann, C. R., Hoogwerf, B. J., Gao, A., Boardman, M. K., Fineman, M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61267-7 · Cited by 565
Self-citationBuse, J. B., Bergenstal, R. M., Glass, L. C., Heilmann, C. R., Lewis, M. S., Kwan, A. Y. M., Hoogwerf, B. J., & Rosenstock, J. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-2-201101180-00300 · Cited by 506 · cited 1×
“IDegLira combines the complementary effects of IDeg and liraglutide on glycemic control (10,11,12).”
BackgroundSelf-citationGough, S. C. L., Bode, B., Woo, V., Rodbard, H. W., Linjawi, S., Poulsen, P., Damgaard, L. H., & Buse, J. B. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70174-3 · Cited by 366 · cited 1×
“IDeg in patients with type 2 diabetes inadequately controlled on metformin with or without pioglitazone supports the benefits of IDegLira compared with IDeg as well as liraglutide (21).”
BackgroundSelf-citation
Cited by
Items 101–200 of 265
Hunt, B., Glah, D. R., & van der Vliet, M. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0266-3 · Cited by 19
“BMI body mass index, HbA1c glycated hemoglobin, HDL high-density lipoprotein, LDL low-density lipoprotein, SBP systolic blood pressure a From [16] b From [17] c DUAL II is a randomized, controlled, double-blind, multinational, treat-to-target trial in which IDegLira was compared with IDeg over 26 weeks of treatment in…”
BackgroundMethodFixed-Dose and Fixed-Ratio Combination Therapies in Type 2 Diabetes
Schlosser, R. (2019) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2019.05.005 · Cited by 22
Miller, E. M., Doshi, A., Grøn, R., Jódar, E., Örsy, P., Ranthe, M. F., Sugimoto, D. H., Tentolouris, N., Viljoen, A., & Billings, L. K. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13851 · Cited by 23
Zenari, L., Porto, A. D., Moliner, L. D., Lugli, F., Guazzoni, V., Groppelli, G., Molteni, L., Bracaccia, M., Frison, V., Simioni, N., et al. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00945-4 · Cited by 18
Raya, P. M., Ampudia‐Blasco, F. J., Hunt, B., Martin, V., Thorsted, B. L., Basse, A., & Price, H. C. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13660 · Cited by 17
“caemia compared with basal insulin and basal-bolus insulin regimens.(3,4) Similarly, IDegLira has been shown to offer improved”
de Wit, H. M., Vervoort, G., Jansen, H. J., de Galan, B. E., & Tack, C. J. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12447 · Cited by 21
Vedtofte, L., Knop, F. K., & Vilsbøll, T. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1288715 · Cited by 19
“4% of IDegLira-treated patients in DUAL I extension [24,25], DUAL II [26], DUAL IV [32], and DUAL V [27], respectively.”
BackgroundMethodInfluentialSelf-citationEricsson, Å., Glah, D. R., Lorenzi, M. F., Jansen, J. P., & Fridhammar, A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191953 · Cited by 23
Injectable Coformulations in Diabetology
Kalra, S., & Gupta, Y. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0106-2 · Cited by 17
Visolyi, G. Á., Domján, B. A., Svébis, M. M., Péterfi, A., Lovasz, B. D., Mészáros, S., Horváth, V. J., & Tabák, Á. G. (2023) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2023.03.002 · Cited by 18
“The previous RCTs, their meta-analyses and our results clearly showed that the effect of FRCs on body weight falls between their components: their use is associated with less weight gain compared to insulins and more than GLP-1RAs alone.[9, 11, 13, 16, 38] The limited meta-analyses of Evans et al.”
BackgroundMethodResultInfluentialNon-insulin pharmacological therapies for treating type 1 diabetes
Frandsen, C. S., Dejgaard, T. F., Madsbad, S., & Holst, J. J. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1483339 · Cited by 18
“have shown promising glucose lowering effects and weight loss in T2D (DUAL-studies) [113,114] and may be of interest to use as ‘basal’ insulin in obese persons with T1D still displaying”
BackgroundGoldman, J. D., & Trujillo, J. M. (2017) · Annals of Pharmacotherapy · doi:10.1177/1060028017717281 · Cited by 18
“Another fixed-ratio combination of insulin degludec and liraglutide (IDegLira) has also demonstrated benefit for patients with T2D, showing an equivalent or greater reduction in A1C compared with the component parts, with less weight gain and comparable hypoglycemia to insulin degludec alone.(40,41) IDegLira has been…”
BackgroundJohnson, E. L., Frías, J. P., & Trujillo, J. M. (2018) · Postgraduate Medicine · doi:10.1080/00325481.2018.1452515 · Cited by 16
“formin were 45 and 41 U, respectively [80,81].”
BackgroundPöhlmann, J., Russel-Szymczyk, M., Holík, P., Rychna, K., & Hunt, B. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0569-7 · Cited by 15
Vilsbøll, T., Blevins, T., Jódar, E., Poulter, N. R., Tentolouris, N., Agner, B. F. R., Lehmann, L., & Leiter, L. A. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13675 · Cited by 15
Self-citationWatada, H., Agner, B. F. R., Doshi, A., Bardtrum, L., Ranthe, M. F., & Billings, L. K. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00730-y · Cited by 17
Lingvay, I., Harris, S. B., Jaeckel, E., Chandarana, K., Ranthe, M. F., & Jódar, E. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13043 · Cited by 15
“pants uncontrolled on oral antidiabetic drugs (OADs; DUAL I, IV and VI), on glucagon-like peptide-1 receptor agonists (GLP-1RAs) and OADs (DUAL III),(8) or on basal insulin and OADs (DUAL II and V).(9,10) Received: 15 March 2017 Revised: 6 June 2017 Accepted: 19 June 2017”
BackgroundFrias, P. F., & Frías, J. P. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0926-8 · Cited by 15
Raccah, D. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2016.11.007 · Cited by 15
Kvapil, M., Prázný, M., Holik, P., Rychna, K., & Hunt, B. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0323-y · Cited by 15
“The results also confirmed that hypoglycemia was numerically lower with IDegLira versus IDeg [20].”
ResultEfficacy and Safety of Ideglira in Older Patients with Type 2 Diabetes
Lingvay, I., Handelsman, Y., Linjawi, S., Vilsbøll, T., Halladin, N., Ranc, K., & Liebl, A. (2018) · Endocrine Practice · doi:10.4158/ep-2018-0284 · Cited by 18
Self-citationAroda, V. R., Arulandu, J. R., & Cannon, A. J. (2018) · Clinical Diabetes · doi:10.2337/cd17-0065 · Cited by 13
Szépkúti, S., Bandur, S., Kovács, G., Ferenci, T., Svébis, M. M., Turbucz, P., & Tabák, Á. G. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-01139-8 · Cited by 15
“6 kg) or with basal insulins in DUAL I, II, V, and VIII (0–3 kg) [12, 15, 18, 19].”
BackgroundLong-term safety and efficacy of insulin degludec in the management of type 2 diabetes
Kerlan, V., Thuillier, P., & Alavi, Z. (2015) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s54953 · Cited by 15
“0001) and mean weight reduction.(27) However, the hypoglycemia rate was comparable in both groups.”
BackgroundØstergaard, L., Frandsen, C. S., Dejgaard, T. F., & Madsbad, S. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1313109 · Cited by 14
“1% greater, and the rate of confirmed hypoglycemia was lower, with IDegLira, as compared with insulin degludec alone [11].”
BackgroundMethodInfluentialPsota, M., Psenkova, M., Racekova, N., de Arellano, A. R., Vandebrouck, T., & Hunt, B. (2017) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s143127 · Cited by 14
“20 The proportion of smokers was based on the trial data, but the number of cigarettes smoked per day was assumed to be the same as the general Slovakian population.”
Home, P. D., Aroda, V. R., Blonde, L., Guyot, P., Shaunik, A., Fazeli, M. S., Goswami, H. H., Kalra, S., & Pourrahmat, M. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14136 · Cited by 14
“For example, IDegLira was initiated at a higher insulin dose and titrated to a lower FPG target than iGlarLixi.(14,17) However, the final mean insulin doses were similar, so the HbA1c and hypoglycaemia findings might also reflect a difference in effective GLP-1RA/insulin ratio between the preparations.”
BackgroundResultKaneto, H., Koshida, R., & Baxter, M. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14095 · Cited by 12
“%) in DUAL I Japan.64,68 The mean daily insulin doses at study end were lower for IDegLira than for insulin degludec: 27.7 U vs. 34.8 U in DUAL I Japan and 37.6 U vs. 41.2 U in DUAL II Japan.64,68 Outcomes with IDegLira treatment were also better than with iDeg in the equivalent global DUAL I60 and DUAL II61 trials wi…”
ResultInfluentialThe role of glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
Onge, E. S., Miller, S. A., Clements, E. A., Celauro, L., & Barnes, K. (2017) · Journal of Translational Internal Medicine · doi:10.1515/jtim-2017-0015 · Cited by 13
“[53-56] The addition of liraglutide to basal insulin was studied in 413 T2DM patients in a randomized, parallel, 26-week study.[54] In this trial, a fixed dose combination of liraglutide plus insulin degludec was compared to degludec alone in patients currently taking metformin with or without sulfonylureas/glinides.”
BackgroundHarris, K., & Nealy, K. L. (2017) · Annals of Pharmacotherapy · doi:10.1177/1060028017726348 · Cited by 14
“In patients previously receiving insulin, hypoglycemia occurred in 23% to 28% of patients receiving IDegLira, which was similar to that for insulin degludec but lower than that for insulin glargine (49%).(24,25) In all trials, rates of severe hypoglycemia were low and less than that with insulin degludec alone.”
BackgroundResultVilsbøll, T., Vora, J. P., Jarlov, H., Kvist, K., & Blonde, L. (2016) · Clinical Drug Investigation · doi:10.1007/s40261-016-0376-0 · Cited by 12
Self-citationSegal, A. R., Vootla, T., & Beaser, R. S. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2016.06.009 · Cited by 14
Blumer, I. R., Pettus, J., & Cavaiola, T. S. (2018) · Postgraduate Medicine · doi:10.1080/00325481.2018.1450058 · Cited by 11
“GI adverse events associated with the fixed-ratio combination therapies are generally mild to moderate in severity with low rates of treatment discontinuation due to GI disturbances [22].”
BackgroundLoreto, C. D., Celleno, R., Pezzuto, D., Ambrosi, F., Bellavita, S., Biagini, M., Passeri, M., & Sindaco, P. D. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01564-z · Cited by 12
“…the comprehensive DUAL clinical trial program [10], which documented efficacy and safety of IDeg-Lira in patients with uncontrolled T2D on oral antidiabetic drugs (DUAL I, IV, and VI) [11–13], GLP-1RAs (DUAL III) [14], basal insulin (DUAL II and V) [15, 16], and basal-bolus insulin (DUAL VII) [17].”
BackgroundPöhlmann, J., Montagnoli, R., Lastoria, G., Parekh, W., Markert, M., & Hunt, B. (2019) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s218746 · Cited by 11
“and assumed to be the same in both arms of the costeffectiveness analysis.(7) Baseline age was 56.”
BackgroundMethodInfluentialHandelsman, Y., Muskiet, M. H. A., & Meneilly, G. S. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01126-x · Cited by 12
Komatsu, M., Watada, H., Kaneko, S., Agner, B. F. R., Nishida, T., & Kaku, K. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13525 · Cited by 12
Haluzík, M., Taybani, Z. J., Araszkiewicz, A., Cerghizan, A., Mankovsky, B., Zuhdi, A., & Malecki, M. T. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01610-w · Cited by 12
“IDegLira was also associated with fewer gastrointestinal AEs than with liraglutide alone [17, 18].”
BackgroundMethodCandido, R., Nicolucci, A., Larosa, M., Rossi, M. C., Napoli, R., Gabellieri, E., Tortato, E., Rabini, R. A., Crazzolara, D., Lucibelli, L., et al. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.07.025 · Cited by 11
Eliasson, B., Ekelund, J., Miftaraj, M., Ranthe, M. F., MÅRDBY, A.-C. M., Fernandes, J. D. D. R., & Svensson, A. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00872-4 · Cited by 11
Lisco, G., Tullio, A. D., Guastamacchia, E., & Triggiani, V. (2020) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530320666200705211224 · Cited by 13
Translating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes
SKOLNIK, N., Prato, S. D., Blonde, L., Galstyan, G. R., & Rosenstock, J. (2021) · Advances in Therapy · doi:10.1007/s12325-020-01614-5 · Cited by 10
Tibaldi, J. M., Mercado, M. E., & Strong, J. L. (2020) · Clinical Diabetes · doi:10.2337/cd20-0014 · Cited by 10
Fadini, G. P., Buzzetti, R., Pitocco, D., Tortato, E., Scatena, A., Lamacchia, O., Lastoria, G., Simoni, L., Consoli, A., & REX study group (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15486 · Cited by 12
“5,6 22 The European multicentre real-world retrospective study EXTRA showed significant reductions in HbA1c and body weight after ≥ 6 months of treatment with IDe-gLira in patients coming from a multiple daily-dose insulin injection regimen.”
BackgroundHorváth, L., Novodvorský, P., & Haluzík, M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16645 · Cited by 10
“46 Initiation of iGlarLixi in this group of patients was at 26 weeks non-inferior to initiation of BIAsp 30 in relation to glycaemic control (LS mean between group difference in HbA1c (cid:1) 0.2% [97.5% CI: (cid:1) 0.4, (cid:1) 0.1]; p < 0.001), but was superior in relation to BW change (LS mean…”
InfluentialNew fixed dose chemical combinations: the way forward for better diabetes type II management?
Abdulsalim, S., Vayalil, M. P., & Miraj, S. S. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1241235 · Cited by 9
“Trial results shows the combination drugs given to patients with diabetes, who are inadequately controlled on the oral agents metformin and pioglitazone, was also shown to have a low risk for weight gain, hypoglycemia, and gastrointestinal side effects [52].”
BackgroundHome, P. D., Mehta, R., Hafidh, K., Gurova, O. Y., Alvarez, A., Serafini, P. R., & Pourrahmat, M. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14518 · Cited by 9
IDegLira for type 2 diabetes: a systematic review and meta-analysis
Liu, Y., Li, X., Zheng, Y., Wang, X., & Wang, X. (2023) · Endocrine · doi:10.1007/s12020-023-03543-z · Cited by 10
Dempsey, M. A., Mocarski, M., Langer, J., & Hunt, B. (2018) · Journal of Medical Economics · doi:10.1080/13696998.2018.1513406 · Cited by 10
Valencia, W., Flórez, H., & Palacio, A. (2019) · Drugs & Aging · doi:10.1007/s40266-019-00706-4 · Cited by 8
An update on the safety of insulin-GLP-1 receptor agonist combinations in type 2 diabetes mellitus
Novodvorský, P., & Haluzík, M. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1978974 · Cited by 13
Nomoto, H. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i3.188 · Cited by 9
Wilding, J. P. H., & Bain, S. C. (2015) · Diabetic Medicine · doi:10.1111/dme.13021 · Cited by 8
“0 DUAL II (Buse et al. 2014) [63] 26 weeks IDegLira 45 dose steps (45 U; 1.”
BackgroundTreatment with GLP-1 Receptor Agonists
Madsbad, S., & Holst, J. J. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_20-1 · Cited by 9
Billings, L. K., Agner, B. F. R., Altuntaş, Y., Grøn, R., Halladin, N., Klonoff, D. C., Tentolouris, N., & Jódar, E. (2020) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820906888 · Cited by 8
“%) with no weight gain and without hypoglycemia were significantly greater with IDegLira than BB insulin therapy across all HbA1c, BMI, and duration of diabetes subgroups (supplemental Figure S1).”
BackgroundMethodInfluentialFadini, G. P., Buzzetti, R., Fittipaldi, M. R., D’Incau, F., Porto, A. D., Girelli, A., Simoni, L., Lastoria, G., Consoli, A., REX study group, et al. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01287-z · Cited by 8
“and VI) [7–9], GLP-1RAs (DUAL III) [10], basal insulin (DUAL II and V) [11, 12], and basal-bo-”
GLP-1 receptor agonists and basal insulin in type 2 diabetes
Young, L., & Buse, J. B. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61409-4 · Cited by 8
Self-citationNew Medications for the Treatment of Diabetes
Garg, S. K., Rewers, A. H., & Aktürk, H. K. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.2512 · Cited by 8
Tran, E. (2017) · Clinical Diabetes · doi:10.2337/cd17-0037 · Cited by 8
SKOLNIK, N., Hinnen, D., Kiriakov, Y., MAGWIRE, M. L., & White, J. R. (2018) · Clinical Diabetes · doi:10.2337/cd17-0048 · Cited by 9
Cowart, K., & Carris, N. W. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16502 · Cited by 7
“40 In the context of FRCs, while the GLP-1 RA component may mitigate the weight gain associated with basal insulin, 41,42 insulin therapy is still associated with a net increase in body weight and hypoglycaemia risk vs. not using insulin.”
Wali, A. F., Rangraze, I. R., Khan, S. S., Mufti, U., El‐Tanani, M., & Rizzo, M. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1736380 · Cited by 7
A primer on concentrated insulins: what an internist should know
Barnosky, A., Shah, L., Meah, F. A., Emanuele, N., Emanuele, M. A., & Mazhari, A. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1159909 · Cited by 8
Tramunt, B., Disse, E., Chevalier, N., Bordier, L., Cazals, L., Dupuy, O., Marre, M., Matar, O., Meyer, L., Noilhan, C., et al. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01327-8 · Cited by 7
Vargas‐Uricoechea, H., Frías, J. P., & Vargas-Sierra, H. D. (2023) · The Review of Diabetic Studies · doi:10.1900/rds.2023.19.14 · Cited by 10
Cannon, A. J., Bargiota, Α., Billings, L. K., Hunt, B., Leiter, L. A., Malkin, S. J. P., Mocarski, M., Ranthe, M. F., Schiffman, A. B., & Doshi, A. (2019) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2019.19035 · Cited by 7
Abusnana, S., Alawadi, F., Aly, H., Bashier, A. M., Dhanwal, D. K., Halasa, T., Jallo, M. K. I., Medina, J., & Singhal, S. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110183 · Cited by 8
Fano, M. D., Mazzieri, A., Fanelli, C. G., Mancinetti, F., Xenos, D., Boccardi, V., & Porcellati, F. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112119 · Cited by 6
Morales, J., & Merker, L. (2015) · Advances in Therapy · doi:10.1007/s12325-015-0208-2 · Cited by 7
“This was so that the relative contribution of the liraglutide component towards the overall efficacy of IDegLira could be judged more clearly, and was a regulatory requirement from the US Food and Drug Administration [56].”
BackgroundInfluentialMeneghini, L., Doshi, A., Gouet, D., Vilsbøll, T., Begtrup, K., Örsy, P., Ranthe, M. F., & Lingvay, I. (2019) · Diabetic Medicine · doi:10.1111/dme.14178 · Cited by 6
Self-citationGhosh, S. K., Unnikrishnan, A. G., Saboo, B., Kesavadev, J., Aravind, S. R., Bajaj, S., Rajput, R., Seshadri, K., Verma, N., Gupta, A., et al. (2017) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2017.03.045 · Cited by 7
Terauchi, Y., Yabe, D., Kaneto, H., Amano, A., Baxter, M., Watanabe, D., Watada, H., & Inagaki, N. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14139 · Cited by 6
Đekić, D., Bojić, M., Janež, A., Majanović, S. K., Hadžimušović, I. G., Ković, T., & Mihalevska, S. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01407-3 · Cited by 6
Combination therapies in the management of type 2 diabetes: the use of insulin degludec/liraglutide
Minze, M. G., & Chastain, L. M. (2016) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s73579 · Cited by 6
Préparations insuliniques au cours de la dernière décennie.
Monnier, L., & Colette, C. (2018) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(18)30034-8 · Cited by 5
Bolli, G. B., Porcellati, F., Lucidi, P., Fanelli, C. G., Perseghin, G., Horowitz, M., & Owens, D. R. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16616 · Cited by 6
“28 In DUAL III the efficacy and safety of IDegLira was compared with that of unchanged GLP-1 receptor agonist (liraglutide or exenatide) therapy.”
Blumer, I. R., Novak, L. M., Edelman, S. V., & Cavaiola, T. S. (2019) · Clinical Diabetes · doi:10.2337/cd18-0102 · Cited by 5
Han, G., Hu, S., Zhang, X., Qiu, Z.-K., & Huang, Z. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1011624 · Cited by 5
Wang, R., Luo, S., Xiao, Z., & Zhou, Z. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3752 · Cited by 4
Malik, R. A., Anderson, J., Russo, G. T., Amani, M. E. A., Adaş, M., Alvarez, A., Lauand, F., Li, X., & Khunti, K. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16591 · Cited by 5
Lauri, G., Arcidiacono, P. G., Facciorusso, A., Capurso, G., & Tacelli, M. (2026) · Pancreatology · doi:10.1016/j.pan.2026.04.005 · Cited by 4
Rincón, A. R., Henao, D. C., Omeara, M., Oliveros, J., Assaf, J., Ordóñez, J. E., Prasad, P., & Alzate-Vinasco, M. A. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01593-8 · Cited by 4
“Fixed‑ratio combinations of basal insulin with a glucagon‑like peptide‑1 receptor agonist (GLP‑1RA) minimize injection burden while balancing the risk of hypoglyce‑ mia and weight gain [1, 2].”
Vilsbøll, T., Fu, A., Kellerer, M., Kumar, B., Søgaard, S. B., & Goldenberg, R. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16328 · Cited by 5
Self-citationSimpson, R., & King, A. B. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.1017562 · Cited by 4
“5–10% who were taking 20–40 U of basal insulin (plus metformin with or without sulphonylurea (SU)/ glinide therapy) to replace their basal insulin with either IDegLira or IDeg [39].”
MethodMcCarty, D. J., Olenik, A., & McCarty, B. P. (2018) · Journal of Pharmacy Practice · doi:10.1177/0897190018764984 · Cited by 4
“Doses for both arms were titrated twice weekly using FPG to a target FPG of 72 to 90 mg/dL with a capped IDeg and IDegLira dose of 50 units.(13) At the end of the 26-week study, there was a 1.”
BackgroundMethodResultInfluentialShibuki, K., Shimada, S., & Aoyama, T. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102474 · Cited by 4
Khunti, K. K., Mohan, V., Jain, S. M., Boesgaard, T. W., Begtrup, K., & Sethi, B. K. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0252-9 · Cited by 4
“The analysis includes participants uncontrolled on oral antidiabetic drugs (OADs) in DUAL I and DUAL IV and participants uncontrolled on basal insulin and OADs in DUAL II.”
BackgroundMethodInfluentialNauck, M. A., Punov, V., Kang, Y. M., & Lim, S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70613 · Cited by 6
Open questions on basal insulin therapy in T2D: a Delphi consensus
Delphi Board, Alberto, A., Roberto, A., Angelo, A., Baggiore, C., cesare, B., Bonadonna, R. C., Giuseppe, C. S. M., Andrea, D. P., Lorenzo, D. C., et al. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02285-2 · Cited by 3
Gangopadhyay, K. K., Majumdar, S., Sinha, B., KOVIL, R. R., & Baruah, M. P. (2020) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2020.100057 · Cited by 3
Wei, R., Wang, W., Huang, X., Qiao, J., Huang, J., Xing, C., Pan, Q., & Guo, L. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01141-7 · Cited by 4
Candido, R., Nicolucci, A., Larosa, M., Rossi, M. C., Napoli, R., Gabellieri, E., Tortato, E., Rabini, R. A., Crazzolara, D., Lucibelli, L., et al. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.03.023 · Cited by 5
Clinical Use of IDegLira: Initiation to Titration After Basal Insulin
Warren, M., & Steel, D. (2019) · Clinical Diabetes · doi:10.2337/cd19-0015 · Cited by 3
“Hypoglycemia rateswere similar for IDegLira and degludec (DUAL II), probably because the dose of degludec was capped at 50 units (because this trial assessed the contribution of the liraglutide component of IDegLira) (23), whereas in the two trials using IGlar U100, the basal insulin dose was not capped, and hypoglyce…”
MethodResultNumber-Based Approach to Insulin Taxonomy
Kalra, S., & Gupta, Y. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0129-8 · Cited by 3
Vedtofte, L., Knop, F. K., & Vilsbøll, T. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.1029455 · Cited by 3
Self-citationBaker, D. E. (2017) · Hospital Pharmacy · doi:10.1177/0018578717715383 · Cited by 3
TRAUTMANN, M. E., & Vora, J. P. (2018) · Diabetic Medicine · doi:10.1111/dme.13610 · Cited by 3
HRAMIAK, I. M., Gerstein, H. C., Leiter, L. A., Yale, J., BAJAJ, H. S., Stewart, J. A., Toutounji, M.-J., & Harris, S. B. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14787 · Cited by 3
Fixed ratio combinations GLP-1RA and basal insulin: literature review
Куркин, Д. В., Bakulin, D. A., Morkovin, E. I., Strygin, A. V., Gorbunova, Y. V., Волотова, Е. В., Robertus, A. I., Макаренко, И. Е., Saparova, V. B., Васильевич, Д. Р., et al. (2024) · Problems of Endocrinology · doi:10.14341/probl13312 · Cited by 4
“Так как при этом средние суточные дозы инсулина деглудек как в монопрепарате, так и в комбинации с лираглутидом были сопоставимы (в среднем 45 ЕД), это указывает на то, что наблюдаемая разница в результатах лечения была связана с арГПП-1 в составе фиксированной комбинации [23].”
Umpierrez, G. E., Gill, J., Hood, D. A., Li, X., & Núñez, A. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16075 · Cited by 3
Metadata
- Authors
- Buse, J. B., Vilsbøll, T., Thurman, J., Blevins, T. C., Langbakke, I. H., Bøttcher, S. G., & Rodbard, H. W.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- University of Copenhagen (DK)
- SSM Health Care (US)
- Texas Diabetes & Endocrinology (US)
- Novo Nordisk (Denmark) (DK)
- Endocrine and Metabolic Consultants, Clinical Research, Rockville, MD
- Corresponding author
- Buse, John B.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2014-10-10
- Volume
- 37
- Issue
- 11
- Pages
- 2926-2933
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2126862523
- Cited by
- 259
- References
- 27
- Citations by year
- 2026: 10 · 2025: 13 · 2024: 10 · 2023: 11 · 2022: 14 · 2021: 14 · 2020: 16 · 2019: 30 · 2018: 39 · 2017: 41 · 2016: 30 · 2015: 26 · 2014: 4
- FWCI
- 26.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk Fonden (NNF12OC1015904)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- insulin degludec, liraglutide, IDegLira, type 2 diabetes, glycemic control, HbA1c, weight loss, hypoglycemia, basal insulin, metformin, GLP-1 receptor agonists, nausea, fixed-dose combination
- MeSH terms
- Liraglutide, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Combinations, Drug Therapy, Combination, Female, Humans, Hypoglycemia, Hypoglycemic Agents, Male, Metformin, Middle Aged, Sulfonylurea Compounds, Weight Loss, Treatment Outcome, Insulin, Long-Acting, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.